C-FEJZBioViva
AAV gene therapy, CMV gene therapy, cellular aging
editinggene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FEJZ
C-FEJZC-FEJZAAV gene therapy, CMV gene therapy, cellular aging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
BioViva AAV gene therapy, CMV gene therapy, cellular aging
BioViva says it is committed to lengthening healthy human lifespans with AAV and CMV gene therapy. Its platform is described as helping patients' cells behave more youthfully and ward off degeneration from aging. The company also operates CodeKeeper, an open access database for gene therapy.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
BioViva — Early mechanism · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…
Source: Deterministic